Allos Raises $5M to Apply Causal AI Across Complex Drug Reformulation

Allos AI today announced $5 million in seed financing led by Oxford Science Enterprises (OSE) to commercialize the industry's ...
FOX8 Cleveland

BioNxt Signs Definitive Agreement For 100% Acquisition of IP And Co-Development of Cladribine ODF Drug Reformulation for The Treatment of Multiple Sclerosis

VANCOUVER, BC / ACCESSWIRE / November 13, 2023 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report that it has signed a definitive agreement (the ...
Morningstar

BioNxt Reports Sublingual Cladribine Multiple Sclerosis Drug Milestones Including Large-Animal Study for Validation and Dosing Optimization

VANCOUVER,BC / ACCESS Newswire / September 29, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience company specializing in innovative drug delivery ...
MarketWatch

Proton Pump Inhibitors (PPIs) Market to Grow by USD 819.5 Million (2025-2029) with Drug Reformulation Boosting the Market, Report on How AI is Redefining Market Landscape ...

NEW YORK, Feb. 5, 2025 /PRNewswire/ -- Report with market evolution powered by AI - The global proton pump inhibitors (PPIs) market size is estimated to grow by USD 819.5 million from 2025-2029, ...
KOIN 6

BioNxt Signs LOI for Acquisition of IP and Co-Development of ODF Drug Reformulation for Neurodegenerative Disease

VANCOUVER, BC / ACCESSWIRE / August 2, 2023 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report that it has signed a non-binding letter of intent ...
Fierce Pharma

Regulatory tracker: GSK's Exdensur gains approval in 2 indications in Japan

Welcome to Fierce Pharma's regulatory tracker for the first half of 2026. | In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key ...